All In Biotech

Drug Trial Radar · NCT07256392

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

1,370

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Celldex TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials. This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • barzolvolimabBiological

    Subcutaneous Administration

  • Standard of CareOther

    Observational/Standard of Care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to disease worsening or treatment failure through Week 52 based on the occurrence of UAS7 (Urticaria Activity Score) of 16 or greater.Time frame: From Day 1 (baseline) to Week 52.
  2. Time to disease worsening or treatment failure through Week 52 based on the occurrence of the discontinuation of barzolvolimab in Group 2 due to lack of efficacy or to a treatment related adverse event.Time frame: From Day 1 (baseline) to Week 52.
  3. Time to disease worsening or treatment failure through Week 52 based on the occurrence of first use of strongly confounding prohibited medication (Group 1 or 2) or use of barzolvolimab in Group 1.Time frame: From Day 1 (baseline) to Week 52.

Locations

201 sites in 30 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama

  • Medical Research of Arizona

    Scottsdale, Arizona

  • Center for Dermatology & Plastic Surgery - Avacare

    Scottsdale, Arizona

  • Kern Research

    Bakersfield, California

  • Allergy and Asthma Associates of Southern California - Laguna Niguel - CRN

    Laguna Niguel, California

  • Dermatology Research Associates

    Los Angeles, California

  • LA Universal Research Center, Inc.

    Los Angeles, California

  • Asthma and Allergy Associates

    Colorado Springs, Colorado

  • Encore Medical Research of Boynton Beach LLC

    Boynton Beach, Florida

  • Dolphin Medical Research

    Doral, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • GSI Clinical Research

    Margate, Florida

  • Miami Dade Medical Research Institute, LLC

    Miami, Florida

  • Deluxe Health Center

    Miami Lakes, Florida

  • Sarasota Clinical Research

    Sarasota, Florida

  • GCP, Global Clinical Professionals

    St. Petersburg, Florida

  • Advanced Clinical Research Institute (ACRI) - Florida

    Tampa, Florida

  • Centricity Research Columbus Dermatology

    Columbus, Georgia

  • Endeavor Health

    Skokie, Illinois

  • The South Bend Clinic - Avacare

    South Bend, Indiana

  • Allergy and Asthma Specialists PSC

    Owensboro, Kentucky

  • John Hopkins University

    Baltimore, Maryland

  • DermAssociates, LLC

    Rockville, Maryland

  • Institute for Asthma and Allergy

    Wheaton, Maryland

  • Michigan Center for Research Co., LLC

    Clarkston, Michigan

  • Respiratory Medicine Research Institute of Michigan PLC

    Ypsilanti, Michigan

  • The Derm Institute of West Michigan

    Caledonia, Missouri

  • Midwest Clinical Research

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Montana Medical Research, Inc.

    Missoula, Montana

  • Skin Specialists, PC dba Schlessinger MD

    Omaha, Nebraska

  • Allergy Partners of NJ, PC

    Ocean City, New Jersey

  • Markowitz Medical PLLC dba OptiSkin Medical

    New York, New York

  • Bexley Dermatology Research

    Bexley, Ohio

  • Auni Allergy

    Findlay, Ohio

  • Toledo Institute for Clinical Research

    Toledo, Ohio

  • Portland Allergy and Asthma

    Clackamas, Oregon

  • Clinical Partners LLC

    Johnston, Rhode Island

  • Alina Clinical Trials LLC

    Dallas, Texas

  • Western Sky Medical Research

    El Paso, Texas

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.